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To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine
(ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 patients with
advanced acute myeloid leukaemia were included in this sequential Bayesian phase I dose-finding trial. A starting dose of
0.5mgm
 2day
 1 was explored with subsequent dose escalations of 1, 3, 5 and 6mgm
 2day
 1. Myelosuppression was constant.
The MTD was estimated as the dose level of 5mgm
 2day
 1 for 9 consecutive days by s.c. route. Dose-limiting toxicities were
hyperglycaemia with hyperosmolar coma at 3mgm
 2, and (i) one anasarque and haematemesis, (ii) one life-threatening pulmonary
aspergillosis, (iii) one skin rash and (iv) one scalp pain at dose level of 5mgm
 2day
 1. The mean half-life of ssHHT was 11.0173.4h,
the volume of distribution at steady state was 271.4lkg
 1 and the plasma clearance was 11.6710.4lh
 1. Eleven of the 12 patients
with circulating leukaemic cells had blood blast clearance, two achieved complete remission and one with blast crisis of CMML
returned in chronic phase. The recommended daily dose of ssHHT on the 9-day schedule is 5mgm
 2day
 1.
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Homoharringtonine (HHT) (Cephalotaxine, 40-methyl (20R)-hydroxy-
20-(400-hydroxy-400-methylpentyl)-butanedioate (ester), [3(R)]- (9CI))
is a cephalotaxus alkaloid obtained by extraction from the
evergreen tree Cephalotaxus sp present in China. Seeds of this
genus of conifers were part of the traditional Chinese medicine
(Huang et al, 1983). In the 1970s, collaboration between US and
Chinese investigators led to isolation of the active extract of
Cephalotaxus. Homoharringtonines (and its analogues) are
inhibitor of protein synthesis with an effect on DNA that may be
important. Their effects are dose and time dependent (Huang,
1975). Homoharringtonine was found to be a selective inhibitor of
transpeptidation during the elongation cycle (Fresno et al, 1977;
Tujebajeva et al, 1989; Zhou et al, 1995). Moreover, recent studies
on chronic myeloid leukaemia (CML) suggest both apoptosis
and differentiation as potential downstream effectors of HHT
(Kuliczkowski, 1989; O’Brien et al, 1993; Visani et al, 1997).
Homoharringtonine had been shown to induce apoptosis in
different types of leukaemic cells in vitro and the HHT-induced
apoptotic cascade is characterised by cytochrome c release and
caspase activation (Cai et al, 2001). More recently, HHT has been
shown to regulate vascular endothelial growth factor expression in
K562 cells (Ye and Lin, 2004). Preclinical studies demonstrated a
wide range of cytotoxic effects mainly directed at rapidly proliferat-
ing cells, irrespective of their lymphoid or myeloid origin (Takemura
et al, 1985; Baguley et al, 1989). In vitro combination with other
cytotoxic agents was consistently nonsynergistic with the notable
exception of cytarabine (Wilkoff et al, 1989; Zhou et al, 1990).
Original studies of HHT in cancer and leukaemia patients were
dated from the 1970s in China. Phase I trials were later performed in
the US using purified alkaloids. Chinese studies were summarised by
Grem et al (1988) with data available for 350 patients with
leukaemia. Almost 25% of the acute myeloid leukaemia (AML)
patients achieved complete remission (CR), but these results were
difficult to evaluate (Grem et al, 1988). In US, purified HHT was
tested first in bolus infusion (Neidhart et al, 1983; Legha et al,1 9 8 4 ;
Stewart and Krakoff, 1985) and later replaced by continuous infusion
schedule to avert HHT-associated cardiovascular complications
(Coonley et al, 1983; Neidhart et al, 1986). Five phase I/II clinical
studies in patients with acute leukaemia were conducted (excluding
myelodysplasia (MDS), APL or paediatric AML) with variable
schedule of continuous infusion with CR rate ranging from 0 to 25%
(Warrell et al, 1985; Kantarjian et al, 1989; Feldman et al, 1992a,b)
(for complete reference, see Kantarjian et al (2001)).
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sHomoharringtonine is currently widely used in China for the
treatment of AML, but the extraction from the barks of
Cephalotaxus sp raised the problem of extinction of the raw
material (scarcity and poor growth rate of Cephalotaxus sp) and
the presence of impurities (at least 1% of related compounds).
Therefore, a highly purified semisynthetic HHT, using the leaves of
the tree, was produced by Oncopharm Corporation with the
perspective of registration.
In this context, we conducted a sequential phase I dose-finding
clinical study in order to determine the maximum-tolerated dose
(MTD) and pharmacokinetic of semisynthetic homoharringtonine
(ssHHT). We choose the subcutaneous (s.c.) route to facilitate the
administration of the drug, especially in the elderly patients, given
as a twice daily s.c. injection for 9 days, in patients with advanced
myeloid leukaemia.
PATIENTS AND METHODS
Eligibility (patients’ selection)
The study was approved by the Local Ethics Committee at the
Ho ˆtel Dieu Hospital. Adult patients (418 and o80 years old) with
a WHO performance status p3 and with documented advanced
myeloid malignancies were eligible for the study, that is, either (i)
AML refractory to one (age 460 years) or two (p60 years)
induction courses of chemotherapy or in first relapse or more;
relapse after autologous stem cell transplantation or allogeneic
stem cell transplantation without possibility of allogeneic lympho-
cytes re-injection; (ii) accelerated or acute myeloproliferative
disorders not responding to conventional treatments; (iii) MDS
refractory to chemotherapy or in relapse after treatment (chemo-
therapy or stem cell transplantation); (iv) CML in accelerated or
acute phase or refractory to interferon a. Patients provided signed,
informed consent. Those patients who received chemotherapy
within 4 weeks of study entry, with active severe infection, and
with cardiac, renal or liver dysfunctions, were excluded. Pregnant
and lactating women were excluded.
Treatment plan and follow-up studies
On entry, all patients received appropriate supportive care,
including hydratation, alkalinisation of the urine, allopurinol at
the discretion of the treating physician and diagnostic evaluation
and treatment of the documented or suspected infections.
Prophylactic antiemetics were given to all patients. Menstruating
women received hormone therapy to prevent menstruation.
Patients were transfused to maintain haemoglobin level 48gdl
 1
and platelets 410 10
3ml
 1, or as clinically indicated. Haemato-
poietic growth factors were not permitted, with exceptions granted
at the discretion of the principal investigator.
Protocol treatment consisted of one 9-day course of chemo-
therapy with ssHHT administered by s.c. route twice a day.
Following the cycle of chemotherapy, an additional course of
ssHHT could be administered in case of response at the discretion
of the treating physician, or any other additional chemotherapy.
Semisynthetic homoharringtonine was manufactured by Onco-
pharm (Le Mans, France).
Trial design and dose allocation rule
The design of this dose-finding phase I clinical trial was chosen to
assess the MTD of ssHHT in the treatment of patients with
advanced myeloid leukaemia. The MTD was defined as the dose
that achieves a dose-limiting toxicity (DLT) in 33% of patients.
Five dose levels were tested, namely 0.5, 1, 3, 5 and
6mgm
 2day
 1. The continual reassessment method (CRM)
(O’Quigley et al, 1990; Garrett-Mayer, 2006; O’Quigley and Zohar,
2006) was used as the dose allocation rule in the trial. It is based on
a mathematical modelling of dose–DLT relationship, iteratively
updated using Bayes theorem along the trial, as follows. First,
before trial onset, each dose level is arbitrarily associated with
initial guesses of DLT probability by the investigator. These initial
guesses, which relied on his (her) personal experience and on
literature, were fixed at 0.05, 0.1, 0.15, 0.33 and 0.5, respectively.
The uncertainty in this dose–DLT relationship is incorporated
into a prior. Then, patient accrual begins, with grouped inclusions
of three patients per dose level. The first cohort is administered the
first dose level. Then, on the basis of observed responses (DLT or
not) of patient cohort, DLT probabilities of all dose levels are
updated using Bayes theorem. The dose level associated with an
updated DLT probability close to 33% is recommended to be
administered to the next patient cohort. All this process is re-run
until fixed sample size is reached, or in case of fulfilled stopping
criteria measuring futility of trial continuation (Zohar and
Chevret, 2001).
Assessment of toxicity and response
Dose-limiting toxicity was defined, using National Cancer Institute
Common Toxicity Criteria (version 2.0), as at least grade 2
neurological or urinary toxicities, at least grade 3 cardiac toxicity
and higher than grade 3 pulmonary and digestive toxicities. All
other toxicities were considered as limiting if they were graded at
least 3. Persistent myelosuppression defined by neutrophil
o500ml
 1 and/or platelets o20000ml
 1 associated with empty
bone marrow for 40 days or more was also considered as DLT.
Local tolerance at the point of injection was analysed apart from
pain and local reaction.
Patient response was evaluated by the examination of marrow
and peripheral blood smears, and assessed using criteria
established by the National Cancer Institute workshop (Cheson
et al, 1990). Complete remission was defined as follows: absolute
neutrophil count X1500ml
 1, platelets X100 10
3ml
 1, absence
of leukaemic blast in peripheral blood, 420% cellularity of bone
marrow with maturation of all the cell lines, o5% leukaemic blasts
in the bone marrow and absence of Auer rods. Partial remission
was similarly defined, except that the percentage of blast in the
marrow was between 5 and 20%, and Auer rods could be present as
long as the percentage of the blasts was p5%. Bone marrow
leukemic cell clearance was checked at the end of ssHHT treatment
(D10) if no leukaemic cells were circulating. If there was a response
on the basis of peripheral blood differential, bone marrow
examination was performed at day 28 or whenever the ANC
recovered to more than 1 10
3ml
 1, and in any case at day 40 in
case of persisting pancytopaenia without circulating leukaemic
cells.
Pharmacokinetic studies
Blood samples (6ml) were collected in sodium heparin tubes at
12h after the administration on day 3, at 0.25, 0.5, 0.75, 1, 2, 4, 8
and 12h after the administration on day 5 and at 4, 8, 12, 24, 36
and 48h after the last injection on day 9. Samples were
immediately centrifuged at 3000g for 10min and then plasma
was divided into two aliquots of at least 1.5ml and frozen at  201C
until the time of analysis. Plasma samples were assayed by a
specific and sensitive liquid chromatographic assay with fluori-
metric detection by monitoring the emission at 320nm with
excitation wavelength of 280nm. Analytical column was a 5-mm
Lichrospher
s C18 column (250mm 4mm I.D.) (Merck, Darm-
stadt, Germany). Sample preparation (1ml) consisted of addition
of internal standard (0.1ml of quinidine 50mgml
 1), solvent
extraction 2.5ml of ethyl acetate and evaporation to dryness for
50min at 601C. The residue was dissolved in 100ml of mobile
phase. An 80ml aliquot was injected onto the column. The mobile
phase was tetrahydrofurane-acetonitrile-citrate/phosphate buffer
A phase I dose-finding and pharmacokinetic study
VL e ´vy et al
254
British Journal of Cancer (2006) 95(3), 253–259 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sadjusted to pH 4.2 (5/15/80, vv
 1). Flow rate was 0.8mlmin
 1. The
retention times of ssHHT and IS quinidine were 5.4 and 8.4min,
respectively. Between-run and within-run coefficients of variation,
measured at nine concentrations (1–60ngml
 1), were less than
11.0%. The lower limit of quantification of this assay was
1ngml
 1.
Estimates of pharmacokinetics parameters for ssHHT were
derived from individual concentration–time data sets by non-
compartmental analysis using the software package WinNonLin
version 4.0 (Pharsight Corporation, Mountain View, CA, USA).
The peak plasma, trough plasma concentrations and the time to
peak concentrations were the observed values observed at day 5.
The area under the plasma concentration vs time curve (AUC) was
calculated using the linear trapezoidal method from time zero to
the time of the final quantifiable concentration. The AUC was then
extrapolated to infinity (AUCinf) after the last injection by dividing
the last measured concentration by the rate constant of the
terminal phase (k), which was determined by linear regression
analysis of the final three or four time points of the log-linear
concentration–time plot. The apparent s.c. total plasma clearance
of ssHHT (CL/F) was calculated by dividing the administered dose
by the observed AUCinf. The apparent volume of distribution (Vdb/
F) was defined as CL/k after the last injection. The terminal
elimination half-life (T1/2) was defined as ln2/k after the last
injection at day 9. Pharmacokinetic data were reported as mean
and standard deviation.
Statistical estimation
All along the trial, updated DLT probability of each dose level was
iteratively computed after each completed cohort of three patients,
using the BPCT software (Zohar et al, 2003). Stopping criteria,
aiming at detecting futility of trial continuation, were also
computed. They are based on the computation of predictive gains
from further inclusions, both on the estimated DLT probability of
the MTD and on precision of DLT probability of the MTD as
measured on the width of its 95% credibility interval. Trial is
recommended to stop when expected gains appear too tiny (ref.).
Qualitative and quantitative results were expressed as percen-
tage and median (Q1–Q3), respectively, using R 8.1 software (the
R development core team, 2003). Survival curve was estimated by
the Kaplan–Meier method, using SPLUS2000 software (MathSoft
Inc., Seattle, WA, USA). The terminal elimination half-life of
ssHHT was analysed as a function of ssHHT dose level using the
Kruskal–Wallis test.
RESULTS
General
Between February 2001 and July 2003, 19 patients were registered
into the study. The median age of study participants was 57 years
(range, 20–79 years), with eight patients (42%) aged over 60 years.
There were eight men (42%) and 11 women (58%). Three (16%)
subjects had a baseline performance status (WHO) of 0, 8 (42%) of
1, 7 (37%) of 2 and (5%) of 3. Sixteen (84%) patients had an AML,
among them two (10.5%) had secondary AML (one MDS and one
CMML). Two (10.5%) patients had accelerated CML and one acute
phase of CMML (5%). Among the 16 AML patients, seven (44%)
were in first relapse, three (19%) in second relapse and three (19%)
in third relapse. One (6%) patient was in first relapse after
allogeneic stem cell transplantation and two (12.5%) patients were
primary refractory to chemotherapy. Among the cohort, nine
patients (47%) had received high-dose Ara-C, two (10%) were
allografted and two (10%) were autografted.
Among the 19 patients, 18 (95%) were treated and evaluable.
One patient (5%) died from progressive disease before evaluation.
Thus, all the results are presented on the 18 evaluated patients.
Estimation of the MTD
The assigned ssHHT dose levels and observed responses in terms
of DLT of the 18 assessable patients are listed in Table 1. The first
cohort of three patients was treated at 0.5mgm
 2day
 1 with no
DLT. None of the three patients exhibited DLT, resulting in
updated DLT probabilities for the five dose levels of 0.001, 0.003,
0.006, 0.035 and 0.11, respectively. As the fifth dose level was
associated with DLT probability of 0.11, close to 0.33, it should
have been recommended to the next three patient cohorts.
Nevertheless, for ethical reasons, investigators preferred not to
skip up to the fifth highest dose level, but the third dose level.
Thus, the second patient cohort was administered 3mgm
 2day
 1.
One DLT out of three was observed. Incorporated in the analysis,
the updated dose–DLT relationship showed increased DLT
probability at each dose level. The fourth dose level,
5mgm
 2day
 1, was then recommended from the third up to the
sixth patient cohort.
Based on the six patient cohorts, stopping trial decision was
made by the expert committee, with three over four stopping
criteria detecting futility of trial continuation. The estimated DLT
probability associated with the dose level of 5mgm
 2 would have
Table 1 Updated DLT probabilities of the five tested dose levels, computed after each newly included cohort of three patients per dose level through the
use of Bayes theorem
HHT-loading dose (mgm
 2day
 1)
Initial guesses of toxicity probability
0.5 1 3 5 6
Updated estimated probability of DLT
Cohort
Administrated dose
(mgm
 2day
 1)
Clinical
response 0.5 0.1 0.15 0.33 0.50
1 0.5 NT NT NT 0.001 0.003 0.006 0.035 0.11
2 3 NT NT T 0.07 0.14 0.19 0.39 0.55
3 5 NT NT T 0.07 0.13 0.19 0.38 0.54
4 5 NT NT NT 0.03 0.07 0.11 0.27 0.45
5 5 NT T NT 0.04 0.08 0.12 0.29 0.46
6 5 T NT T 0.06 0.12 0.17 0.36 0.53
DLT¼dose-limiting toxicity; HHT¼homoharringtonine; NT¼no toxicity; T¼DLT. In bold: the dose level closest to the toxicity target (33%).
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sbeen expected to change by less than 5% even if three further
patients were included.
At the end of the trial, the MTD was selected to be the fifth dose
level, that is, 5mgm
 2day
 1, with estimated DLT probability of
36.1% (95% credibility interval: 15.8–58.6%). Dose-limiting
toxicities were recorded in four (33%) out of the 12 patients who
actually received the 5mgm
 2day
 1 ssHHT-loading dose.
Toxicity
The designation and grade of all significant toxicities observed
during the treatment are summarised in Table 2a. Five DLTs were
observed, one grade 3 hyperglycaemia with hyperosmolar coma at
3mgm
 2 requiring insulin and rehydration, and four DLTs at dose
level of 5mgm
 2day
 1: (i) one anasarque and haematemesis, (ii)
one life-threatening pulmonary aspergillosis, (iii) one skin rash and
(iv) one scalp pain. The only significant toxicities experienced by
the three patients who received the starting dose of
0.5mgm
 2day
 1 were grade 2 digestive toxicities in two patients
and grade 2 infectious disease in one patient. The second patient
entered into the first dose level died at day 19 owing to progressive
disease (AML). Similarly, three patients were treated with the third
dose level (3mgm
 2day
 1) without any notable drug-related
toxicities, aside from one grade 3 endocrine (diabetes with
hyperosmolar coma) and one grade 3 infectious episode (systemic
candidosis) observed in the same patient. Twelve patients were
treated at the estimated MTD (5mgm
 2day
 1); in this setting, five
grade 3 and one grade 4 toxicities were noted. Grade 3 toxicities
were one infectious (pneumopathy), one digestive (haematemesis),
one cardiovascular (anasarque), one pain (scalp) and two
cutaneous. Grade 4 toxicity was an invasive aspergillosis (Table 2b).
Myelosuppression occurred in 100% of the patients, with a
median duration of 31 days (24–45 days).
Local tolerance was carefully monitored for all patients. Six
(33%) patients had a grade 1 pain at the site of injection, 12
patients (67%) experienced local erythema and three (17%) a local
haematoma. From the 313 injections given, 16 (5%), 70 (22%) and
6 (2%) presented pain, local erythema or haematoma, respectively.
All theses toxicities were grade 1.
Response and survival
Antileukaemic effect is summarised in Table 3. Blood leukaemic
clearance occurred in 12 patients with leukaemic-circulating cells,
including one patient at 0.5mgm
 2 and two at 3mgm
 2. Bone
marrow blast clearance at the end of chemotherapy was evaluated
at day 10 in 14 patients. Five patients showed an empty bone
marrow, one out of three patients at 3mgm
 2 and four out of 10
patients at the DLT. Two patients (11%) achieved CR (duration 4
Table 2a Summary of clinical toxicities during the trial
No of toxicities (grade 1/grade 2/grade 3/grade 4)
at dose levels of
0.5mgm
 2
(n¼three
patients)
3mgm
 2
(n¼three
patients)
5mgm
 2
(n¼12
patients)
Cardiovascular — — 5/2/1/0
Cutaneous 2/0/0/0 1/0/0/0 6/1/2/0
Digestive 1/2/0/0 2/1/0/0 2/2/1/0
Endocrinian — 0/0/1/0 2/4/0/0
Neurological — — 1/2/0/0
Infectious 1/1/0/0 0/0/1/0 1/1/0/1
Muscular — — 2/0/0/0
Pain 1/0/0/0 1/0/0/0 4/1/1/0
Total 5/3/0/0 4/1/2/0 23/13/5/1
Table 2b Detailed grade 3 and grade 4 clinical toxicities per patient
during the trial
Patient
no.
Dose
(mgm
 2)
Type of
toxicity
Grade of
toxicity Details DLT
UPN 7 3 Endocrinian 3 Diabetes Yes
Infectious 3 Candidiasis
septicaemia
No
UPN 10 5 Cardiovascular 3 Anasarque Yes
Digestive 3 Haematemesis Yes
UPN 12 5 Infectious 3 Pneumonia No
UPN 15 5 Infectious 4 Aspergillosis Yes
UPN 17 5 Cutaneous 3 Rash Yes
UPN 19 5 Pain 3 Scalp Yes
DLT¼dose-limiting toxicity.
Table 3 In vivo antileukaemic effect of ssHHT
Patient
no.
Dose
(mgm
 2)
Blood blast
clearance
Bone marrow
D10
Blood/bm at the
end of cytopaenia Result of treatment
1 0.5 D8 94% blasts Leukaemic Blood blast clearance
2 0.5 No clearance Not done Leukaemic No effect
3 0.5 Not evaluable Not done Leukaemic No effect
4 3 D7 74% blasts Leukaemic Blood blast clearance
6 3 Not evaluable 63% blasts Leukaemic No effect
7 3 D4 Clearance Death Blood and bm clearance
8 5 D6 70% blasts Leukaemic Blood blast clearance
9 5 D11 Clearance 15% in bm Blood and bm clearance
10 5 D7 Not done Death Blood blast clearance
11 5 Not evaluable 76% blasts 18% in bm Reduction of bone marrow blasts
12 5 Not evaluable 25% blasts Leukaemic No effect
13 5 D3 Clearance Aplastic at D36 Blood and bm clearance
14 5 D5 Clearance 4% in bm CR (4 months)
15 5 D4 Not done 4% in bm CR (3 months)
16 5 D6 41% blasts 42% in bm Blood blast clearance
17 5 Not evaluable 12% blasts 5.5% in bm Blood and bm clearance
18 5 D7 Clearance 7.5% in bm Return to CMML (6 months)
19 5 D6 Not done Aplastic at D38 Blood and bm clearance
CMML, chronic myelomonocytic leukaemia; CR, complete remission.
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smonths and 3 months, respectively), and one patient with blast
crisis of CMML return in chronic phase for 6 months. These three
patients had been treated at the estimated MTD (5mgm
 2day
 1).
The two patients who achieved CR had been treated for AML in
first relapse and second relapse, treated by conventional dauno-
rubicine Ara-C combination and high-dose Ara-C, respectively.
The patient with CMML who returned to chronic phase was treated
after the failure of daunorubicin and conventional doses of Ara-C.
The median survival of the 18 treated patients was 4.2 months and
survival at 6 months was 38.9% (95% CI, 21.8–69.4%) (Figure 1).
Pharmacokinetics
Pharmacokinetic studies were performed in 17 patients with
complete concentration–time profiles available. Figure 2 shows
plasma concentration vs time profiles of ssHHT at day 9 after the
last injection at the dose levels of 0.5mgm
 2day
 1 (n¼3),
3mgm
 2day
 1 (n¼2) and 5mgm
 2day
 1 (n¼12). The mean
pharmacokinetic parameters of ssHHT are summarised in Table 4.
Interpatient variability in pharmacokinetic parameters was
low, more particularly for Cmax at the 5mgm
 2day
 1 level
(CV¼21.1%). Tmax was short and consistent with s.c. absorption
(range 0.25–1.1h). The AUCs but not Cmax increased in near
proportion with increasing doses of ssHHT. Disappearance of
ssHHT from the central plasma compartment was characterised by
elimination in an apparent monoexponential manner. The
estimate apparent terminal half-life was relatively consistent in
all patients, exhibiting a mean value of 11.0173.4h when all doses
were combined. T1/2 was dose independent (P¼0.52). Evolution in
Cmin between days 5 and 9 shows no apparent accumulation of
ssHHT. Plasma concentrations of ssHHT were still detectable 48h
after last injection at day 9.
DISCUSSION
Traditional induction regimen for AML, such as combination of
cytarabine and an anthracycline, consistently leads to CR;
however, relapse is common. Only 25–45% of patients younger
than 60 years remain in CR at 4 years (Bennett et al, 1997). Patients
who develop AML after a pre-existing MDS have even worse
responses (Kantarjian et al, 1997). New approaches are therefore
needed to address this problem.
Homoharringtonine has demonstrated promising activity in
several haematological malignancies, and has been extensively
studied in the 1980s, demonstrating an interesting efficacy in CML
and AML. However, hypotension was the DLT when HHT was used
at high doses and/or in short schedule infusions, whereas
myelosuppression was DLT for continuous low-dose infusions.
Nonhaematologic toxicities were considered as mild and rever-
sible. Moreover, despite its significant antileukaemic activity, its
difficult production, the unreliability of source supply, the
difficulty of extraction and the low level of purity of product
limited its evaluation in large randomised studies or its use in
clinical practice.
The results of the present phase I study, in which a purer
and easier to produce semisynthetic form of HHT is given
by s.c. route, prove that the regimen is feasible in patients with
advanced/refractory acute leukaemia, with an acceptable toxicity
profile.
Our pharmacokinetic data indicate low interpatient variability
after s.c. administration of ssHHT. The volume of distribution,
total plasma clearance and terminal elimination half-life of ssHHT
are very close to pharmacokinetic data published with continuous
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Figure 1 Kaplan–Meier survival curve in treated patients (n¼18).
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Figure 2 Concentration–time profiles of HHT at dose levels ranging
from 0.5 to 5mgm
 2day
 1 after last injection at day 9. Data from the
same dose levels were grouped and are presented as mean values
(symbols)7s.e. (error bar). The legend indicates each of the dose levels
used.
Table 4 HHT Pharmacokinetic parameters
Dose
Cmax day 5
(ngml
 1)
Tmax day 5
(h)
Cmin day 5
(ngml
 1)
Cmin day 9
(ngml
 1)
AUC day 9
(nghml
 1) Vdb/F (lkg
 1)C L / F (lh
 1) T1/2 (h)
mgm
 2day
 1 mg No. Pts Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
0.5 0.9–1.0 3 10.5 8.8 1.0 0.12 3.4 0.9 169 38 1.52 0.39 5.9 1.60 13.4 3.8
3 4.8–5.4 2 78.0 18.2 0.6 0.53 27.4 27.9 14.7 8.3 441 291 2.54 0.75 14.2 8.77 8.9 3.7
5 7.0–10.0 12 96.1 20.3 0.6 0.43 31.3 16.7 25.6 20.3 909 550 2.02 1.43 11.6 10.4 10.8 3.2
Grand mean 11.01 3.4*
*P-value for Kruskall–Wallis test (P¼0.52).
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et al (1986) explored the pharmacokinetic of continuous infusion
of HHT at doses of 3–4mgm
 2day
 1. Vdb/F, CL/F and T1/2 were
2.470.4lkg
 1, 12.471.9lh
 1 and 9.371.4h, respectively. Semi-
synthetic homoharringtonine inhibits protein synthesis in a dose-
and time-dependent manner. Peak plasma of ssHHT at 3 and
5mgm
 2day
 1 levels were above the concentrations required in
vitro to inhibit 50% of the growth of human leukaemic HL-60 cells
(Zhou et al, 1995).
The design of the trial used the CRM, a Bayesian sequential
design, to determine the MTD. This method allowed us a precise
estimation of the MTD, with an estimated toxicity probability at
the 5mgm
 2 dosage of 36.1% (95% credibility interval: 15.8–
58.6%), 12 patients being treated at this dose. This estimation
compares favourably with classical estimation of the MTD in phase
I trial using, for example, the standard 3þ3 method in which a
maximum of six patients are treated at the MTD.
This trial demonstrates that, in patients with advanced AML, the
MTD of ssHHT is 5mgm
 2day
 1 during 9 days by s.c. route. This
regimen is primarily associated with a haematological toxicity,
with a prolonged myelosuppression and, in several cases, febrile
neutropenia with life-threatening infection in two cases.
Antileukaemic activity was not the primary end point of this
study, and patient population was heavily pretreated with few
young patients or patients having been treated by allogeneic stem
cell transplantation. Nevertheless, three out of 18 (17%) patients
benefited from the treatment, experiencing either CR or return to a
chronic phase of a CMML. Taken together with the toxicity profile
of the drug, this suggests that ssHHT should be tested early in the
course of the disease.
Subcutaneous dose schedule of ssHHT may provide easier
administration for patients and will permit the exploration of
novel dosing schedule in chronic disease such as MDS or AML in
remission as maintenance therapy (Buchner et al, 2001). Moreover,
consideration should be given to re-exploring the potential value
of ssHHT in other haematological malignancies such as CML
(O’Brien et al, 2003; Marin et al, 2005), specially in cases of bcr-abl
mutation T315I, refractory to several tyrosine kinase inhibitors.
Furthermore, manipulation in the side chain of ssHHT may
provide second-generation analogues that may have a broader or
different spectrum of activity.
In conclusion, the recommended dose of ssHHT by s.c. route
is5mgm
 2day
 1 for 9 days. Semisynthetic homoharringtonine is
well tolerated and has a favourable pharmacokinetic profile
with low interpatient variability. It merits further evaluation in
phase II studies. A clinical development plan aiming for
registration of ssHHT is currently ongoing, sponsored by
ChemGenex Phamraceutical Ltd (CA, USA) and Stragen Pharma
(Geneva, Switzerland).
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